



SCS
Swiss Chemical
Society


Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Complete archive of CHIMIA volumes from 1947 to present day now available online



Thanks to a generous grant from the SCNAT Platform Chemistry and the hard work of Martin Brändle, David Spichiger and Raphael Wittwer, the complete archive of CHIMIA from 1947 to the present day has been digitalized and is now available on CHIMIA.ch (<https://www.chimia.ch/chimia/issue/archive>). The archive is open access

and use of the search function will help you to locate subjects of interest and articles from well-known Swiss authors. Take a look!

Open Mandate at the SCS: CHIMIA Editor-in-Chief



The CHIMIA Editorial Board is looking for an Editor-in-Chief to replace Prof. Catherine Housecroft from 2027.

The Editor-in-Chief is responsible for planning the special topic issues on an annual basis, inviting and supporting Guest Editors and ensuring the scientific quality of the articles. He/she has the final say in whether to accept a submission.

The Editor-in-Chief is also directly responsible for one issue a year that presents the work of the SCS major prizewinners, and for one issue every other year introducing young faculty in chemistry in Switzerland.

The Editor-in-Chief is also responsible for handling the small number of spontaneous submissions of manuscripts to CHIMIA which may be considered for the 'Notes' section.

This role would suit someone who is well embedded in the Swiss chemistry community and is interested in scientific publishing and supporting the activities of the Swiss Chemical Society. The role takes an estimated 1-2 hour per week.

See <https://www.chimia.ch/chimia/announcement/view/2> for more details or contact Catherine Housecroft (catherine.housecroft@unibas.ch) or David Spichiger (spichiger@scg.ch).

Open Mandate at the SCS: Chairperson of the CHIMIA Editorial Board



The CHIMIA Editorial Board is looking for a new Chairperson of the Editorial Board to replace Dr. Gillian Harvey from the beginning of 2026.

The Chairperson of the CHIMIA Editorial Board has a range of administrative duties and is involved in the strategic development of the journal.

The administrative duties include running the Editorial Board meetings (3 p.a.), preparing the editorial programme for each issue, checking invoices from external service providers and supporting the technical editor.

The Chairperson is an ex officio member of the SCS Board of Directors and Executive Board where he/she represents the interests of CHIMIA and is also involved in all other Board business. In addition, the Chairperson is involved in the strategic development of CHIMIA, most importantly collaboration with other diamond open access journals in Switzerland to ensure recognition of this publishing format and to secure sustainability and funding. This includes active participation in the newly formed association Diamond+ that was formed to fulfil these aims.

This role would suit someone from the Swiss chemistry community who is interested in open access publishing and supporting the activities of the Swiss Chemical Society. The role takes an estimated 1 day per month.

See <https://www.chimia.ch/chimia/announcement/view/2> for more details or contact Gillian Harvey (harvey@scg.ch) or David Spichiger (spichiger@scg.ch)

A Warm Welcome to Our New Members!



Period: 28.01. – 28.04.2025

Vikrant Adsool, Neuhausen am Rheinfall - Claudia Bissattini Alessi, Dübendorf - Klaudia Aniela Bossi Zabielska, La Rippe - Maximilian Bremerich, Basel - Daniel Camilo Cano Blanco, Ennetbaden - Simon Clemens, Zurich - Erica Clinton, Klingnau - Luca Condrau, Tavannes - Pierre-Yves Dapsens,

La Plaine - Simone Delessert, Elgg - Pierre Emmanuel Doulain, Aclens - Elias Dressler, Zurich - Philippe Dupau, Valserhone (FR) - Andrew J. F. Edmunds, Basel - Reto Erni, Basel - Jonas Eschmann, Fribourg - Nicholas Evans, Bath (UK) - Jonas Forner, Bern - Wei Fu, Geneva - Liliana Galvez Vazquez, Bern - Olivia Gamp, Zurich - Catherine Gandara, La Plaine - Marcus Gastreich, Sankt Augustin (DE) - Divyansh Gautam, Bern - Roman Goy, Steinen (DE) - Gino Graf, Steffisburg - Manon Guivier, Fribourg - Anais Herren, Cogne (IT) - Yessine Jemili, Geneva - Isabel Kerschgens, Basel - Ardita Kilaj, Basel - Thibault Kläy, Bourignon - Robin Knüsel, Wiggen - Anton Kudashev, Basel - Amal Kumar, Basel - Tim Kunzmann, Bern - Benjamin Ladet, Fribourg - Joël Landis, Zurich - Harry Lecomte, Meikirch - Minghao Liang, Bern - Weina Liu, Visp - Victoria Lohmann, Zurich - Xiang Longxue, Bern - Guillaume Magnin, Muttens - Olena Mainarovich, Solothurn - Marvin Mendel, Basel - Stefanie Mesch, Basel - Marvin Metzelaars, Zurich - Aman Mishra, Lund (SE) - Ivana Nemethova, Winterthur - Matilde Onofri, Renens - Gay Orlanes, Nussbaumen - Vincent Paillard, Fribourg - Soyeb Pathan, Vadodara (IN) - Patrick Piccione, Lancy - Hesamoddin Rabee, Bern - Hari Priya Ravindran, Wallisellen - Pattaraphon Rodlamul, Sion - Clément Rols, Renens - Ralph Schwidetzky, Buchs - Alessandro Senocrate, Dübendorf - Evelyn Sgroi, Bern - Niklaus Sidler, Basel - Andreas Sieber, Brig-Glis - Olivier Smith,

Sion - Thordis Snaedal, Bern - Aobo Song, Groningen (NL) - Pratap Narayan Soni, Sion - Julia Specht, Zurich - Craig Steven, Zurich - Irina Stradiotto, Sirmach - Pascal Stump, Bern - Frederic Su, Gailingen am Hochrhein (DE) - Yun Hao Shawn Teh, Baar - Auguste Tetenoire, Lausanne - Veronica Tona, Zurich - Federica Torrigino, Mendrisio - Katharina Trapp, Zurich - Evan Vasey, Lausanne - Matej Vizovisek, Zurich - Kaifeng Wang, Zurich - Micha Weber, Zurich - Penny Wilkie, Sursee - Xin Yu, Bern - Oleg Zaitsev, Bern - Yining Zhu, Bern.

HONORS, AWARDS, APPOINTMENTS

Best Poster Prize Winners at the 17. Freiburger Symposium 2025



Congratulations to the poster prize winners of the 17. Freiburger Symposium 2025 for their outstanding poster presentations. The award included a certificate and prize money of 200 CHF each. The prize was handed over by Dr. Richard Smith, Executive Editor Wiley-VHCA.

Winners:

Fabio Casanova, dsm-firmenich (left),
Pauline Daul, HES-SO Fribourg (middle)
Vincent Freiburghaus, University of Zurich (right)

The objective of the Freiburger Symposium is to regularly provide our members and other interested chemists working in process development and production with opportunities for professional training and networking. The event was organized by the SCS Division of Industrial & Applied Chemistry (DIAC).

Source: <https://scg.ch>

Prof. Sandra Luber, University of Zurich, receives the 2024 Walter Thiel Award



The EuChemS Division of Computational and Theoretical Chemistry awards the 2024 Walter Thiel award to **Prof. Sandra Luber**, University of Zurich. We like to take the opportunity to congratulate Prof. Luber for this recognition.

Sandra Lubers research deals with the development of theoretical methods at the interface of chemistry, biology, physics, and materials science. In particular, approaches derived from quantum mechanics have been in the focus of her work. Together with her team she uses various methods including wavefunction- and density functional theory-based approaches as well as ab initio molecular dynamics, enhanced sampling methods, Quantum Monte Carlo, and quantum mechanics/molecular mechanics. Applications encompass a broad range of systems ranging from (bio-)molecules and functional coordination compounds to condensed phase systems and solar light-driven processes^{[1], [2]}.

The Walter Thiel Award recognizes an outstanding scientific contribution of a young researcher based in a country affiliated to EuChemS. The award is granted every two years. It includes a prize amount of one thousand Euros, the EuChemS Walter Thiel medal and an invitation to present a feature article on the award winning research in Chemistry – A European Journal^[3].

Prof. Walter Thiel was one of the world's leading European theoretical chemists of the late 20th and early 21st century. He was among those who realized the potential of theoretical and computational chemistry, not only to predict and understand a great variety of phenomena in chemistry, physics and biochemistry, but also to establish the route toward the exploration of new processes and provide the answers to many of the questions that challenge our understanding of the world around us^{[3],[4]}.

The EuChemS Walter Thiel Award is sponsored by the Max-Planck-Institute für Kohleforschung, the GDCh, the Swiss Chemical Society, and Chemistry Europe.

[1] <https://www.chem.uzh.ch/en/research/groups/luber.html>

[2] <https://lubergrupp.ch/prof-dr-sandra-luber/>

[3] <https://www.euchems.eu/divisions/computational-chemistry-2/walter-thiel-award/>

[4] Obituary by Alois Fürstner, Benjamin List, Tobias Ritter, Ferdi Schüth, Frank Neese; Wiley online library, 2020.

Source: <https://www.euchems.eu>

Best Poster Prize Winners at the SCS Spring Meeting 2025



Congratulations to the poster prize winners of the SCS Spring Meeting 2025 for their outstanding poster presentations.

The awards included a certificate and prize money of 150 CHF for the runners-up and 200 CHF for the winner.

Winner:

Kaifeng Wang, University of Zurich (right)

Runners-up:


Tzu-Chin Chang Chien, University of Basel (middle)

Abhijit Dutta, University of Bern (left),

The SCS Spring Meeting is a one-day symposium and provides a high-quality program with national and international speakers on a certain topic. The topic of the 2025 symposium was «Electrocatalysis: Current Challenges and Future Perspectives». The topics included the design of colloidal nanocrystals for selective and stable catalysis, the role of high-entropy materials in catalytic behavior, and interfacial transformations governing the oxygen evolution reaction.

Source: <https://scg.ch>

Swiss Chemistry Olympiads 2025: Gold medals for young chemistry talents 2025



From April 21 to 26, 20 high school students and apprentices took part in the final of the Swiss Chemistry Olympiad. In the laboratories of ETH Zurich, they competed in experiments. Four Swiss and four Liechtenstein students won tickets to the United Arab Emirates where they will represent Switzerland and Liechtenstein at the

International Chemistry Olympiad in July.

The four Swiss winners are:

Ruben Locher, Upper Valais Vocational School (VS)

Stanislaw Bektaş, International School of Schaffhausen (SH)

Carl-Philipp Cachej, MNG Rämibühl (ZH)

Maya Post, Cantonal School Hohe Promenade (ZH)

Ruben Locher, who is training to be a chemical laboratory technician at Lonza, was the only professional to make it to first place in the final.

All four gold winners will receive the Swiss Chemical Society's sponsorship prize of CHF 500 per person and a place at the International Chemistry Olympiad (ICHO). Ruben Locher, Stanisław Bektaş and Carl-Philipp Cachej will be traveling to the desert for chemistry for the second time: They took part in the ICHO in Saudi Arabia last year.

Source: <https://chemistry.olympiad.ch/>

Prix Schläfli for Chemistry 2025 awarded to Dr. Hyun Suk Wang, ETH Zurich



Dr. Hyun Suk Wang, ETH Zurich received the Prix Schläfli 2025 for Chemistry for his work on controlled “degradation” of plastics. For his thesis at ETH, the South Korean puzzled over a process to completely recycle plastics. In other words, to fully restore the basic components. He conducted experiment after experiment for six months.

Unsuccessfully. Then, after half a year, a flicker of hope. Half of one per cent of the plastic had indeed been changed back. “This tiny signal showed me that it might work. My motivation returned in full,” recalls Wang.

The breakthrough achieved by the PhD student after the months of frustration not only restored his enthusiasm for his subject, but also won him the Prix Schläfli for Chemistry. The process is called “depolymerisation” and has been studied closely by researchers for years. Controlled breakdown is new. “Plastics consist of long chains,” explains the young materials scientist. He has developed a method that allows these chains to be broken down evenly and slowly, rather than simply disintegrating, as before. It is also possible to precisely determine the chains' structure using this process. “Think of it as blue and red beads on a thread,” explains the 32-year-old. “By using depolymerisation we can control their arrangement.” The South Korean has made an important contribution in two fields with this process. “It is helpful with regard to the circular economy as well as plastics characterisation.”

Source: <https://scnat.ch>

JOURNAL NEWS

Helvetica, Volume 108, Issue 4, April 2025



Editorial

Beginning of Second Mandate as Editors-in-Chief for *Helvetica Chimica Acta*
Eva Hevia, Jérôme Waser

Perspective

Recent Progress in Visible Light-Mediated Synthesis of β -lactams
Suman Pradhan, Shoubhik Das

Research Article

Stability of Shielded Pentacenes under Ambient Conditions
Philipp Ludwig, Paul Kilian, Patrick Mayerhofer, Nikolai Hippchen, Frank Rominger, Jan Freudenberg, Uwe H. F. Bunz

Effect of π -Electron Conjugation on the Chiroptical Properties of Helicene Carbon Nano hoops

Kovida Kovida, Juraj Malinčík, Tomáš Šolomek

NMR Investigation of Lanthanoid (III) Complexes of bbppn (H2b-bppn: *N,N'*-bis(2-hydroxybenzyl)-*N,N'*-bis(2-methylpyridyl)propylene-1,2-diamine)

Annika Matt, Alessandro Prescimone, Daniel Häussinger

Iron-Catalyzed C–H Activation/Aza-Annulation with 2-Butyne for Accessing Methylated Aza-Arenes

Yan Zhang, Rui Shang, Eiichi Nakamura

INDUSTRIAL NEWS

Source: www.chemanager-online.com

Boehringer Ingelheim Opens New R&D Center in Basel

April 7, 2025: NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company's oncology research strategy. The new facility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development to develop transformative cancer therapies. Boehringer Ingelheim's investment in NBE Therapeutics' Basel site is a key move in advancing cancer care. This bolsters its oncology pipeline, expands the ADC portfolio, and complements recent agreements and facility openings. The new center will develop next-generation ADCs, targeting tumor cells while minimizing impact on healthy tissue, enhancing cancer treatment options and patient quality of life. “This investment in a new, cutting-edge research center underscores our strong commitment to deliver breakthrough innovation to people living with cancer,” said Jean Engela, CEO at NBE Therapeutics. “We are confident that this state-of-the-art building will enable our team of scientists to accelerate the development of next-generation ADCs, ultimately impacting the lives of patients battling cancer.” The new facility represents an additional commitment of CHF 27 million (€28.8 million) in ADC R&D over several years. It will provide a sophisticated research environment to accelerate the development of innovative ADC therapies while fostering synergies through access to a broad pool of scientists and experts within the global Boehringer Ingelheim oncology network. “Switzerland offers an unparalleled biotech ecosystem. By strengthening our presence here, we are reinforcing our commitment to advancing innovative cancer treatments,” said Karl Penz, CFO of the Innovation Unit at Boehringer Ingelheim and Chairperson of the NBE Therapeutics Board of Directors. The new R&D center in Basel meets top Swiss sustainability standards, featuring energy-efficient design and responsibly sourced materials, offering 1,826 m² of labs and office space for seamless collaboration within Boehringer Ingelheim's global network.

Ethris and Lonza to Develop Spray-Dried mRNA Respiratory Vaccines

April 9, 2025: Room-temperature stability aims to address the supply chain challenges of mRNA vaccines, including ultra-low-temperature storage and complex delivery systems. This will simplify production, reduce costs, and support scalable vaccine development. Spray-dried formulations of mRNA-based vaccine candidates aim to enable needle-free nasal administration, potentially achieving mucosal immunity. The collaboration's initial focus is developing a nasally delivered mRNA influenza vaccine designed to provide localized immune responses comparable to intramuscular vaccines and reduce vi-

rus transmission. Lonza will provide spray-drying and particle engineering for Ethris's stabilized mRNA and lipid nanoparticles at its Bend site, ensuring ideal properties for respiratory delivery and preserving mRNA activity. Carsten Rudolph, Chief Executive Officer, Ethris, commented: "Lonza's support and leading expertise is an asset and provides unique support as we progress development of our mRNA vaccine technology under the CEPI grant. Together, I believe we are well positioned to create promising non-invasive mucosal vaccine candidates that could potentially transform how respiratory diseases are prevented globally." Jan Vertommen, Vice President, Head of Commercial Development, Advanced Synthesis, Lonza, added: "Spray-drying represents a well-established technique that addresses solubility and other manufacturing and stability challenges. However, its application in the field of DNA and RNA-based products represents a highly innovative approach, with another level of complexity introduced by the presence of LNPs. Combining the expertise of Lonza Bend site's particle engineering team with the innovative SNIM RNA of Ethris, there is great potential to target unmet medical needs in the field of non-invasive vaccine delivery."

Roche Invests \$50 Billion in Pharmaceuticals & Diagnostics

April 23, 2025: These investments further strengthen Roche's already significant US footprint, which includes 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions. They are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include:

- Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California
- A state-of-the-art gene therapy manufacturing facility in Pennsylvania
- A new 900,000 square foot manufacturing centre to support Roche's expanding portfolio of next-generation weight loss medicines (location to be announced)
- A new manufacturing facility for continuous glucose monitoring in Indiana
- A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as a hub for our new cardiovascular, renal, and metabolism research and development efforts
- Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana, and California

"Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today's announced investments underscore our long-standing commitment to research, development, and manufacturing in the US," said Thomas Schinecker, Roche Group CEO. "We are proud of our 110-year legacy in the United States, which has been a key driver for jobs, innovation, and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world." Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the US than it imports. Today, its diagnostics division already has an export surplus from the US to other countries.

From Innovation to Implementation

April 23, 2025: PHARMAP 2025 provided insightful perspectives on the latest trends in pharmaceutical manufacturing, sustainability, automation, and digital transformation. The conference showcased the industry's ongoing innovation and highlighted emerging challenges and solutions shaping the future of pharma.

The event welcomed leading global players, including Sandoz, Merck, Novartis, Bayer, Takeda, F. Hoffmann-La Roche, and Almirall S.A., among many others. As the industry navigates a period marked by cost pressures, regulatory evolution, and increasing demand for sustainability and digitalisation, the Congress provided a business programme full of peer-level exchange, insights, and practical solutions. The 5th-anniversary edition was proudly supported by CryoXpert – the medical division of Dohmeyer – as the Principal Sponsor. A longstanding partner of the Congress, CryoXpert was represented by Frans Mortier, Strategic Sales Manager, who delivered a welcome speech during the opening panel. He also participated in a session on efficiency in pharmaceutical manufacturing. His presentation focused on the rapid development of mRNA-based therapies, outlining the operational shifts required to move from clinical trials to commercial launch. Key points included the importance of regulatory alignment, manufacturing scale-up, and supply chain preparedness in supporting the wider adoption of mRNA technologies. The list of speakers in this session also contained:

- Björn-Thoralf Erxleben, Senior Manager Market Manager Pharma & Biopharma at Shimadzu Europa
 - Antonella Cimatti, CDMO Strategic Account Manager – Morpho, and Giovina Di Meo, Project & Product Lifecycle Management Office Coordinator at Alfasigma
 - Devendra Ridhurkar, CEO at RidNova Pharmaceuticals
- Sustainability also featured prominently in the PHARMAP 2025 agenda. During the opening panel, Stanislav Kazanov, Head of Sustainability at Innowise, delivered an insightful presentation on digital intelligence in green drug manufacturing. He presented case studies showing how pharmaceutical manufacturers have reduced energy consumption and decreased waste through IoT-based monitoring and AI-driven insights. The presentation included implementation strategies and ROI analysis of successful deployments. The topics of the session also referred to:
- digital transformation of drug manufacturing and packaging – presented by Thierry Marchal, Chief Technologist Healthcare EMEA at Ansys
 - strategies for ensuring safe medicines – shown by Chakravarthi AVPS, Global Ambassador at the World Packaging Organisation
 - emerging challenges in pharmaceutical manufacturing – delivered by Ayse Hizli, Director of New Business and Global Partnerships Strategy at Sandoz
 - evolving dynamics of the global supply chain – illustrated by Ton Knipscheer, Executive Director at ECPA (European Co-Packers Association)

The 5th PHARMAP Congress reinforced its role as a dedicated platform for knowledge exchange, strategic alignment, and innovation within pharmaceutical manufacturing and packaging. The next edition of PHARMAP is scheduled for 20–21 April in Amsterdam, the Netherlands. In 2026, PHARMAP will continue to operate in a closed-door format, fostering a focused and confidential environment for high-level dialogue. The agenda explores how pharmaceutical manufacturers can strike a balance between functionality, safety, and brand integrity, what defines a win-win partnership, and how to take personalised medicine to the next level.



Minutes of the 35th (125th) General Assembly

April 24, 2025, 13:45–14:14h,
University of Bern, Freiestrasse 3, 3012
Bern.

1. Welcome, Approval of the Agenda

During the lunch break of the SCS Spring Meeting, Christian Bochet, President, and David Spichiger, Executive Director, opened the assembly. The agenda was approved.

2. Election of the Vote Counter

At the beginning of the meeting, 36 SCS members were present and by the end of the meeting, about 60 participants attended the meeting. The assembly unanimously confirmed Yves Auberson and Richard Smith as vote counters.

3. Minutes from the 34th GA from June 7, 2024

The minutes were published in CHIMIA (2024, 78, No. 7–8, A569 f.). The minutes were approved unanimously and without abstention.

4. Annual Report 2024

The annual report was published in CHIMIA (2025, 79, No. 1–2, A115 ff.). It was approved unanimously.

5. Financial Report 2024 and Audit Report

Operating incomes of CHF 1'775'237 and operating expenses of CHF –1'902'361 result in an operating loss before taxes of CHF –127'124. The portfolio at Bank von Graffenried followed the trend of the financial markets and contributed a surplus of +305'397. Considering taxes, non-periodic income, cost allocation to the funds and the building of 200'000 asset fluctuation buffer an operating loss of CHF –21'569 resulted. The assets of all SCS funds increased by CHF +46'035. As of 31.12.2024 the total assets summed up to CHF 4'944'562.

Audit Report: In the report provided by BDO, no inconsistencies are mentioned, and the financial statement fulfills the legal requirements according to the SCS bylaws and the Swiss Civil law. The assembly approved the financial statement 2024 and the audit report unanimously with no abstention.

6. Discharge the Organs of the Society

The assembly discharged the board members and the financial audit unanimously with six abstentions (board members).

7a. Elections: Executive Board (ExB), Board of Directors (BoD)

All members of the ExB and the BoD are elected at least until the General Assembly 2026. No elections took place.

7b. Elections: Financial Audit.

The assembly confirmed *BDO AG, Bern* unanimously as audit instance for the financials 2025.

8. Membership Fees

The annual membership fees 2026 were approved unanimously:

– Regular member	CHF	150.00
– Student member	CHF	50.00
– Retired member / unemployed members	CHF	80.00
– Institutional member (institutions)	CHF	800.00
– SCS Partnership (institutions)	CHF	3'000.00

Additional Fees for Divisions

– Industrial & Applied Chemistry	– Regular	CHF	20.00
	– Company	CHF	100.00
– Photochemistry Section	– Regular	CHF	40.00
	– Student	CHF	20.00

15% discount on collective memberships for academic research groups.

9. News and Strategic Projects

The Board of Directors and the Head Office will focus on the following, strategic initiatives:

- Review event portfolio
- Finalize digitalization CHIMIA journals 1947–1989
- Collaborate with Aprentas for non-formal education curricula
- Replace SCS membership database and SCS business software
- New SCS Head Office location as of fall 2025/beginning 2026
- Personnel changes: Successors for Gillian Harvey, Catherine Housecroft and Hans Peter Lüthi
- Prepare activities for the 125th anniversary of the SCS

10. Event Outlook 2025

- In 2025, twenty-one conferences and symposia took place or will take place under the direct organization of the SCS. In addition, the SCS is an active partner of seven conferences or summer schools organized by third parties.
- Under the auspices of the DFR four SCS Lectureship take place and a dozen of smaller, local, events will be organized.
- The list of SCS events is available on <https://scg.ch/events>.

Planned Events 2026

- Swiss Snow Symposium, Saas-Almagell, Jan 15–17, 2026
- 6th Swiss Industrial Chemistry Symposium, Basel, Jan 30, 2026
- DMCCB Basel Symposium, Basel, Feb 5, 2026
- *CH*analysis (DAS), Beatenberg, Mar 18–19, 2026
- SCS Spring Meeting, Fribourg, Apr 2026
- Birgenstock Conference, Brunnen, May 3–7, 2026
- SCS Seminar on FlowChemistry, Fribourg, Jun 2026
- Peptide Therapeutics Forum, Basel, Aug 2026
- Summer School, Haute-Nendaz, Aug 16–20, 2026 (topic tbd)
- SCS Fall Meeting, Bern, Aug 27–28, 2026
- Int. Summer School on Electrocatalysis, Aug 30–Sep 3, 2026
- EFMC–ISMC 2026, Basel, Sep 6–10, 2026
- Swiss Chemistry Science Night, Bern, Sep 18, 2026
- Ilmac Lausanne, Beaulieu Lausanne, Sep 23–24, 2026
- Zentralkurs Chemie, Gymer Lebermatt, Köniz, Oct 2026
- Swiss Course on Medicinal Chemistry, Leysin, Oct 2026
- SCS Syngenta Symposium, Stein, Oct 2026
- SCS Seminar on Intellectual Property, Oct/Nov, 2026

11. Varia

No requests to speak were requested from the audience. The President thanked for the confidence and closed the meeting.

Bern, April 23, 2025

Prof. Christian Bochet
President

David Spichiger
Executive Director